Neoadjuvant chemotherapy (NAC) has demonstrated improved five-year overall survival (81.4% versus 77.8%) and disease-free survival (79.2% versus 73.7%) in patients with locally advanced colon cancer compared to upfront surgery followed by adjuvant chemotherapy. Researchers analyzed eight randomized controlled trials involving 3,038 patients, finding NAC to result in better surgical margin outcomes without increasing surgical risks. These findings advocate for NAC as a viable treatment option in managing locally advanced colon cancer.
Journal Article by Sassun R, Sileo A (…) Larson DW et 5 al. in Ann Surg Oncol
© 2025. Society of Surgical Oncology.